PCM
SNDX icon

Peregrine Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Peregrine Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-199,086
Closed -$3.83M – 350
2024
Q3 		$3.83M Buy
199,086
+427
+0.2% +$8.82K 0.12% 239
2024
Q2 		$4.08M Buy
198,659
+2,580
+1% +$54K 0.12% 242
2024
Q1 		$4.67M Buy
196,079
+46
+0% +$1.03K 0.13% 237
2023
Q4 		$4.24M Sell
196,033
-23,941
-11% -$368K 0.13% 236
2023
Q3 		$3.19M Sell
219,974
-13,764
-6% -$260K 0.1% 242
2023
Q2 		$4.89M Buy
+233,738
New +$4.87M 0.13% 240

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return